ByHeart’s ‘bizarre’ response to infant botulism outbreak worries experts

Infant formula maker ByHeart pushed back against regulators in its first responses to the recall, according to experts.

November 14, 2025 Check out STAT+

Sponsored By

Cheyanne Mumphrey/AP ByHeart's 'bizarre' response to infant botulism outbreak worries food safety experts Experts say the formula maker spent three days trying to minimize a dangerous situation. ByHeart says it 'acted immediately' after a call with the FDA By Sarah Todd NIH abruptly places outspoken critic of Trump administration on leave Jenna Norton, an official at the National Institute of Diabetes and Digestive and Kidney Disease, says the move is "intended to make people go silent." By Anil Oza Judge says he'll approve opioid settlement with OxyContin maker Purdue and Sackler family The deal would require family members to contribute up to $7 billion and give up ownership of the company. By Associated Press STEPHANE DE SAKUTIN/AFP via Getty Images Opinion: Why might a 79-year-old man need an MRI of his brain? News of Trump getting an MRI begs a question: What's routine for a man of that age? A neurologist explains age-related issues in a First Opinion essay. By Andrew E. Budson Advocates decry intersex exceptions in trans health bans Procedures done on intersex infants, including vaginoplasty and phalloplasty, are the exact procedures banned for young trans people in many states. By Theresa Gaffney STAT+ | Merck to buy Cidara, maker of a flu prevention drug, for $9.2B Merck is looking for its next blockbusters as its top-selling cancer drug Keytruda faces looming generic competition. By Andrew Joseph Adobe Opinion: Celebrating a new, faster path to gene-editing medicines on demand Fyodor Urnov, an expert on gene-editing medicine, examines a new pathway for CRISPR treatments on demand — and deems it scientifically sound. By Fyodor Urnov Opinion: The era of safe bets in psychiatric medicine is over Biotech and pharma are going "blockbuster or bust" when it comes to developing new psychiatric drugs. By Khutaija Noor

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser